Sofosvel is the global first generic oral tablet for pan-genotypic Chronic Hepatitis C treatment. This combination (Sofosbuvir 400 mg + Valpatasvir 100 mg) drug has been approved by US FDA & European Commission for treatment of patients with all genotypic Chronic Hepatitis C virus infection.

Sofosvel is used without cirrhosis or with compensated cirrhosis, and patients with advanced cirrhosis (Decompensated).

who-logo 125 x 125

“Hepatitis-C Drugs remain unaffordable in many countries”

Beacon Introduces Global Patient Support Program


Life saving drugs are either beyond the reach of general

people or not available in many countries. Because of

the patient exemptions for Bangladeshi companies,

Beacon Pharmaceuticals can manufacture the patented

drugs. As a support to global patient… Read more

Registered & Licensed by Regulatory
Authority of Bangladesh


Sofosvel is a registered product by the Directorate General

of Drug Administration & Licensing Authority (Drugs) of

Bangladesh. Drug Registration Number: 341-294-32

Inclusion Date: 20-07-2016 Valid up to: 19-07-2021

Latest News